Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

PRNewswire/ -- "According to the latest study from BCC Research, the demand for Gene Editing Therapeutics is estimated at $11 ...

On 19, 2024, @Lillyin_London shared a video of farmers protesting in Westminster, London, UK. British farming communities held the demonstration in response to new inheritance tax regulations on ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

“TEASE-1 is the first randomized, controlled trial in Stargardt disease that has shown an efficacy endpoint, which is very exciting as an inherited retinal disease specialist taking care of patients ...

the PWAS Hub allows for disease-specific genetic exploration with analyses distinguished by sex, for male and female subjects. It also accounts for different inheritance patterns, including dominant ...

Healthy.io, the global leader in transforming the smartphone camera into a medical device, announced the results of a new ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence the progression ... Cruchaga and his collaborators had access to a rich ...

President-elect Donald Trump stands to inherit two major public health improvements ... Data from the Centers for Disease Control and Prevention released Tuesday shows meaningful declines in ...

As part of the process to update estimates on the burden of foodborne diseases published in 2015, WHO is conducting a global source attribution study. Presenters in a recent webinar gave an ...

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa ...

Ocugen (NASDAQ: OCGN) Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions] I will now ...